Boothbay Fund Management’s Pacific Biosciences PACB Stock Holding History

Boothbay Fund Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23,608	Closed	-$43.2K	–	1684
2024 Q4	$43.2K	Buy	+23,608	New	+$46.1K	﹤0.01%	1370
2022 Q4	–	Sell	-14,283	Closed	-$83K	–	2338
2022 Q3	$83K	Buy	+14,283	New	+$81.9K	﹤0.01%	2071
2020 Q2	–	Sell	-19,800	Closed	-$61K	–	1077
2020 Q1	$61K	Buy	+19,800	New	+$81.1K	0.01%	772
2016 Q3	–	Sell	-13,080	Closed	-$92K	–	782
2016 Q2	$92K	Sell	13,080 -31,810	-71%	-$291K	0.04%	459
2016 Q1	$382K	Buy	+44,890	New	+$441K	0.1%	316

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boothbay Fund Management's PACB Position: Q1 2025 in Review

Boothbay Fund Management sold out of Pacific Biosciences (PACB) in Q1 2025, closing a stake of 23,608 shares — an estimated $43.2K sold.

Boothbay Fund Management first reported a position in PACB in Q1 2016 and held it in 5 quarters. The position peaked at $382K in Q1 2016. 225 funds tracked by Wall St. Rank hold PACB as of Q1 2025.

Boothbay Fund Management reported no remaining Pacific Biosciences position as of Q1 2025 after selling out during the quarter.
Boothbay Fund Management sold 23,608 Pacific Biosciences shares in Q1 2025, an estimated $43.2K.
Boothbay Fund Management first reported a position in Pacific Biosciences in Q1 2016 and held it in 5 quarters.
Boothbay Fund Management's Pacific Biosciences position peaked at $382K in Q1 2016.
225 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.